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Abstract
Fifty years after the discovery of adeno-associated virus (AAV) and more than 30 years after the first gene
transfer experiment was conducted, dozens of gene therapy clinical trials are in progress, one vector is approved
for use in Europe, and breakthroughs in virus modification and disease modeling are paving the way for a
revolution in the treatment of rare diseases, cancer, as well as HIV. This review will provide a historical
perspective on the progression of AAV for gene therapy from discovery to the clinic, focusing on contributions
from the Samulski lab regarding basic science and cloning of AAV, optimized large-scale production of
vectors, preclinical large animal studies and safety data, vector modifications for improved efficacy, and
successful clinical applications.
Introduction/Historical Perspective
W ith the discovery of ‘‘virus-like’’ particles in adeno-virus (Ad) preparation by Bob Atchison1 and M. David
Hoggan and Wallace Rowe2 in 1965, the journey of a novel
parvovirus began.3 Atchison tentatively referred to the virus
as adeno-associated virus (AAV), and Rowe continued use of
the name (Fig. 1). Early experiments characterized a virus
that replicated poorly, if at all, in human cells in the absence
of Ad. However, it was clear that AAV was immunologically
distinct from any known Ad antigen, and three serotypes
were identified, AAV1, 2, and 3.1 The following years saw
progress in determining that the AAV capsid contained an
ssDNA genome,4,5 that the genome contained inverted ter-
minal repeats (ITRs),6–8 and that these ITRs are structured
as self-priming hairpins that act as origins of genome repli-
cation.9 Sequencing of the AAV2 serotype ITRs was com-
plete by 1980.10 Concomitantly, the latent state of AAV was
observed at NIH when an Ad infection on a panel of cell lines
resulted in the production of AAV. This led to the discovery
that low numbers of AAV genomes were integrated into the
host chromosome,11 thus establishing the foundation for
using AAV as a gene therapy vector based on its lytic (co-
infection with Ad), latent (establishment of persistence in the
absence), bi-phasic life cycle.
Basic Science
Also in the early 1980s, with all molecular biology ex-
periments being conducted using AAV serotype 2, it was
known that the AAV genome was packaged into preformed
capsid proteins.12 Further, a transcription map showed three
overlapping mRNA families from three promoters, p5, p19,
and p40.13,14 The genome appeared divided between left and
right, and three capsids, VP1, VP2, and VP3, were produced
from the p40 promoter on the right side.15 It was unclear
what the left half of the genome encoded, but a replication
function was predicted. What was known, however, was that
the virus could be produced in excess of 100,000 particles
per cell. This ability to produce high yields, the fact that
AAV was not a pathogen, and that the virus could persist all
encouraged further exploration of its use as a gene therapy
delivery platform. Unfortunately, because AAV replicated
in the presence of a lytic virus, there was no easy focus-
forming assay for selection of isolated mutants. Molecular
clones were needed, but the NIH Recombinant DNA Ad-
visory Committee (RAC) guidelines were not clear when it
came to cloning AAV DNA into plasmids. According to
Barrie Carter, a 1980 ASM meeting in Miami Beach con-
vinced the NIH RAC that recombinant DNA viruses like
AAV and Ad could be safely studied in BSL2-approved
laboratories.16 Here, cloning of the AAV genome into plas-
mids became a reality and isolation of wild-type (wt) AAV
infectious clones became a major milestone for the field.
In 1978 as a new graduate student in the lab of Nicholas
Muzyczka, Jude Samulski was tasked with generating a
plasmid containing the AAV genome that could be used to
rescue wild-type AAV virions. Based on Nicholas’s design,
digest of the pBR322 plasmid with PstI generated a linear
molecule to which oligo(dG) was attached to the 3¢ end of
the plasmid, while oligo(dC) was attached to duplex AAV
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DNA17 and allowed to reanneal after melting out at 70C.
The new plasmid was transfected into HB101 E. coli and 50
colonies were obtained. Three plasmids (pSM501, pSM503,
and pSM504) were the correct size for an intact AAV re-
combinant plasmid and restriction digest with diagnostic PstI
enzyme showed that there were no major deletions in the
nonrepeated internal sequences of AAV and that the PstI
reformed during the cloning process to release the terminal
fragments. However, the plasmid preps appeared to contain
mixtures of at least two plasmids that differed from each
other in the AAV terminal resolution sites (trs). Multiple at-
tempts to subclone from pSM501 mixed parental stock al-
lowed for isolation of a plasmid that had the appropriate cut
sites and no trs deletions, pSM620 (named for 620 attempts).
Fortunately, this achieved isolation of a plasmid with the
complete AAV genome that allowed for the rescue of wt
virus by means of plasmid transfection and helper virus in-
fection17 and initiated the current 30-year-long journey to
optimize AAV as a viral vector. In fact, supernatant collected
from 293-31 cells that were transfected with pSM620 and
infected with Ad serotype 5 proved just that, namely, rescue,
replication, and packaging of a molecular clone of wt AAV
from a plasmid substrate. The Carter lab achieved the same
outcome the following year.18 Based on these studies, this
work put in place a system to begin site-directed mutagenesis
across the AAV genome, which in turn lead to the design of
the first-generation of AAV transfer vectors.
While the success of finding one complete plasmid was
encouraging, there were also many other clones identified
that contained deletions within the ITR sequences, from
the left, right, or both sides of the intact AAV genome.
Surprisingly, rescue of plasmids containing only deletion of
the left or right ITR resulted in production of capsids con-
taining wt AAV DNA.19 Of the plasmids containing dele-
tions in both ITRs, only one allowed for rescue of the virus,
though viability was low. In fact, deletion of the remaining
11 bp from the pSM609 ITR resulted in a complete inability
to rescue the virus. This discovery confirmed the necessity
of AAV ITRs for replication, confirmed the AAV replica-
tion model using ‘‘Flip + Flop’’ terminal repeats, and started
the discussion of a model whereby AAV utilizes a mecha-
nism to correct deletions within its ITRs through a process
called ‘‘gene conversion.’’ This set the stage for under-
standing AAV vector concatenation and the recently de-
scribed fragmented AAV vectors described below.19 Shortly
following the generation of AAV clones, the entire sequence
of AAV2 was completed19 and allowed for identification of
the cis-acting origin of replication function of the ITRs and
the trans-acting function of the left and right reading frames
of the AAV genome products.3,20
About this time, the first transduction of mammalian cells
was demonstrated. Hermonat and Muzyczka3 utilized the
ins96(pHM2904) construct, a derivative of pSM620, to gen-
erate a plasmid containing a neomycin resistance gene and
successfully rescued AAV2 virus. The virus was used to in-
fect human Detroit 6 and KB cells, with antibiotic resistance
tested with G41821 and an observed transduction efficacy of
0.4–10%.3 These experiments validated another major mile-
stone in vector development. The authors highlighted areas
that required additional understanding, including expression
from integrated AAV genomes, improved rescue of AAV,
studies of larger DNA inserts, host range mutants, and gene
therapy applications, all of which would assume over the next
30 years.
Continuing work on the basic virology of AAV, Samulski
working with Patrick Hearing and Thomas Shenk at Prin-
ceton reported that deletion of repeated cis-acting sequence
allowed for Ad5 genome replication, but prevented pack-
aging of the genome into viral capsids. Further, a series of
Ad mutants along with AAV mutants engineered in the in-
fectious molecular clone allowed the lab to determine the
sequence required for packaging, successful replication, and
integration.22 Importantly, Samulski also continued work
on the AAV2 pSM620 vector, generating modifications to
facilitate easy swapping of transgenes. The first of these
was psub201. In the plasmid, psub201( + ), the AAV2 cod-
ing domain was flanked with XbaI cleavage sites in a four-
fragment ligation allowing for 96% of the viral gene to be
removed and replaced with transgene sequence of choice to
be easily inserted between the cis-acting ITRs. Additionally,
unique PvuII sites allowed for excision of the entire viral
sequence from the plasmid.23 These studies define early in-
formation concerning the packaging limits of AAV (i.e., 5 kb)
and, with respect to further understanding virus biology,
confirmed a proposed hypothesis about AAV second-strand
DNA synthesis. Specifically, the article demonstrated the
ability to isolate plus- and minus-strand AAV2 genomes as
molecular clones using single-stranded phage DNA-carrying
wt AAV genome and showed that both strands were infec-
tious,23 confirming a hypothesis proposed by Ken Berns and
colleagues for AAV self-primed replication using AAV ITRs.
While significant understanding was being acquired for
various aspects of AAV biology during this phase of sci-
ence, the Samulski lab turned their attention to rate-limiting
FIG. 1. Adeno-associated virus serotype 2 atomic struc-
ture. The surface topology and electrostatics of AAV2 are
shown (modified from Xie et al.71). The 25 nm virion capsid
shown here is composed of 3 viral proteins, VP1, 2, and 3,
and encapsidates an approximately 5 kb ssDNA genome that
has been used to encode and deliver transgenes of interest
for human gene therapy application.
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steps involved in AAV vector production. As an early pre-
cursor to GMP production, a method was established for
generating stocks free of wt helper AAV.24 Using psub201,
the recombinant AAV (rAAV) contained only the terminal
191 nucleotides flanking a neomycin or hygromycin resis-
tance marker gene. Trans-acting functions of helper AAV
were provided by a construct in which the 191 terminal re-
peats of AAV were replaced with Ad sequences that did not
allow the AAV helper DNA to replicate or facilitate re-
combination between viral trans and cis sequences.24 As the
AAV ITRs are only required in cis for replication, this
system allowed for specific generation of rAAV and set
forth years of experimental exploration aimed at improv-
ing the yields of this robust production system. Infection
of human cells with the produced virus resulted in 70% of
established colonies expressing the marker gene. This al-
lowed for generation of drug-resistant human cell lines and
helped establish for the first time that AAV gene expression
was not required for integration into host DNA24 or AAV
transduction.
Now in the early 1990s, as integration was thought to be
key for prolonged gene expression and therapeutic use, it
was important to determine if the vector could be oncogenic.
Robert Kotin, working with leading AAV researchers, de-
termined that wt AAV integration occurs specifically on
the q arm of chromosome 19, a unique finding among
DNA viruses.25,26 Following this work, the Samulski lab
and others continued basic virus research demonstrating that
AAV Rep protein is required for targeting integration and at
the same time began testing AAV for treatment of rare
diseases discussed in the next section. Although all labs
working on AAV during this time were relying on the latent
phase of AAV, namely, integration, no one was prepared for
the observation of Xiao and Samulski that AAV persisted as
concatenated episomes after vector transduction.27
Preclinical Studies
With 25 years of basic AAV research as a foundation,
labs were now attempting gene therapy experiments for
treatment of human diseases. With several hemoglobinop-
athies requiring high-level expression of a transferred glob-
ing gene in erythroid cells, b-globin transfer was the first
AAV expressed transgene explored by the Samulski lab in
collaboration with Chris Walsh at NIH. It was demonstrated
that rAAV encoding the Ac-globin gene could be stably
introduced into human K562 eyrthroleukemia cells and that
expression was equivalent to that of a native Ac-globin
gene.28 This article also demonstrated how expression could
be enhanced with a locus control region (LCR) inserted
before the gene and was the first demonstration of tissue-
specific promoters in an AAV vector context.28 A follow-up
publication made mutations to regions of the hypersensi-
tivity site 2 (HS2) LCR in front of the Ac-globin gene and
demonstrated changes in transcription binding factors that
may be useful for regulating gene expression.29 Again, all of
these early studies utilized in vitro cell lines and gene ex-
pression was tracked with viral integration, which was not
very efficient in most of these cell types.
Moving from in vitro to in vivo, the first reported use of
AAV to express a cystic fibrosis transmembrane conduc-
tance regulator (CFTR) protein in an animal model by Terry
Flotte showed efficient transduction of rabbit lung tissue,
with the AAV-encoded CFTR protein detected in airway
epithelium for up to 6 months following vector adminis-
tration.30 In another in vivo study in rats, for the first time
the denervated striatum of the brain was injected with rAAV
encoding LacZ (AAVlac) or human tyrosine hydroxylase
(AAVth). This treatment resulted in virus-driven gene ex-
pression up to 4 months posttreatment and resulted in sig-
nificant behavioral recovery.31 At this time, many diseases
were being addressed by gene therapies and cardiac disease
was no exception. Intramuscular (i.m.) injection in rat hearts
as well as infusion into porcine circumflex coronary arteries
with AAV lac Z with a human cytomegalovirus immediate-
early promoter caused limited observable inflammation and
gene expression for at least 6 months after infusion.32 These
studies and others provided preliminary safety data and
highlighted the plausibility of gene therapy success.
What was not directly explored in the early studies was
AAV tropism. Studies in the Samulski lab determined that
the expression pattern and longevity of the AAV-encoded
lacZ reporter depends on the area of the brain being stud-
ied.33 Most importantly, for diseases with central nervous
system (CNS) pathology, there were no signs of toxicity
noted. For treatment of metabolic disorders, such as hemo-
philia or Duchenne muscular dystrophy (DMD), targeting of
liver or muscle tissue will be required, respectively. Pre-
vious effort using other vectors (Ad, retrovirus, or naked
DNA) had encountered immune clearance of transduced
cells, but Xiao’s study demonstrated that rAAV could be
applied without an adaptive immune clearance of transduced
cells and that in vivo gene transfer of at least 1.5 years (life
of the mouse) could be achieved.32 This work in collabo-
ration with Xiao and Li was the first study to demonstrate
long-term transduction of AAV in an animal model. Similar
study showing transduction in muscle for 4 months was
published by Barry Byrne and colleagues the same year, and
confirmed the unique but hallmark observation that AAV
persistence was long lived and consistent with expectations
based on viral latent life cycle. Since these initial efforts,
significant progress has been observed determining the ability
to efficiently deliver transgenes to skeletal muscle in mouse,
hamster, canine, and primate models for life of animal, sup-
porting the original studies published by Xiao and Byrne.
Generation of fluorescently labeled rAAV34 allowed for
the first-ever in vivo monitoring of rAAV kinetics and
provided a basis for targeted application of neuronal popu-
lations in human brain therapies following direct infusion
with AAV2.35 What was not expected was the perplexing
observation described by Xiao that the ‘‘in vivo’’ AAV
genomes appeared episomal and not integrated. More con-
fusing was the observation that over time monomeric AAV
genomes were transitioning to ‘‘head to tail’’ concatamers.
This fascinating observation is believed to occur through
AAV ITRs and requires a circular intermediate. Confirma-
tion of nonintegrated high MW episomes was carried out by
Reed Clark and Phil Johnson in an elegant but simple
analysis of genomic versus nongenomic DNA using DNA
nucleases and restriction enzymes. Although the research
community was slowly uncoupling the difference between
in vitro and in vivo experiments, these findings that rAAVs
could be targeted to specific cell types opened a door into
viral tropism modification.
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The lab continued this focus, first examining regulatory
sequences within the ITRs that may determine tissue-
specific expression. It was shown that the terminal repeat
A/D junction element had promoter activity of its own that
may interfere with all regulated expression cassettes.36 This
work built on previous studies that explored the use of
tissue-specific promoters or enhancer elements to optimize
or target rAAV therapies by promoter modifications. Here
enters the advent of the self-complementary (sc)AAV vec-
tors. As preclinical studies highlighted a need for increased
speed of transgene expression and better dose–response
studies, the scAAV eliminated the rate-limiting step of
second-strand synthesis.37,38 The scAAV vectors pioneered
by Doug McCarty were shown to be up to 140% more ef-
fective transducing agents compared with conventional rAAV.
These novel ‘‘double-stranded’’ vectors worked in every
serotype tested and every tissue analyzed, demonstrating a
universal principal of AAV biology with respect to single-
versus double-stranded vector DNA genomes. These re-
agents have now been validated in clinical studies for a
number of indications, including hemophilia, demonstrating
successful expression of factor IX now out 3 years in he-
mophilic patients (St. Jude phase I).
One significant drawback was packaging capacity. About
half of the *5 kb capacity of rAAV vectors is available for
transgene substitution. With this caveat, selection of genetic
disorders based on transgene size suggested a good place to
start when considering AAV vectors. With more than 70%
of all cDNAs averaging 5 kb and smaller, this limitation
appears suitable for a variety of genes. In an effort to
maximize space, the lab carried out a number of promoter
studies to find smaller promoters for use in scAAV that
would allow for similar gene expression and replaced the
traditional 800 bp CMV promoter with a 229 bp fragment of
the mouse methyl-CpG-binding protein-2 (MeCP2), leaving
extra space for transgene packaging.39
Looking to characterize tissue tropism more, a cross-
packaging assay of different serotypes containing the same
ITR from AAV2 (hybrid vectors) with the genome packaged
in capsids from serotypes 1–5 was evaluated by Joseph Ra-
binowitz in the lab. Here it was identified that rAAV1 was
optimal for transduction of muscle, while serotypes 5 and 4
were most efficient at transduction of the retina with AAV4
only transducing the retinal pigment epithelium.40 Many se-
rotype comparison studies have been done since and pro-
vided much needed starting points for optimal capsid designs.
With the advent of ‘‘hybrid AAV vectors,’’ an onslaught of
studies determining AAV serotype tropism ensued. In the
Samulski lab, these studies led to the hypothesis that one
could generate chimeric AAV capsids that may process novel
tropisms not yet described. This was first described by Joe
Rabinowitz, a post doc in the lab, with mixing experiments
where different AAV serotype helper plasmids were mixed at
varying ratios during vector production (25:75, 50:50, and
75:25 ratios of AAV1 and 2, respectively) and then chimeric
AAV capsids were evaluated for transduction tropism.
On the basis of these observations, Dawn Bowles (another
post doc) validated that this approach could be achieved
using only small fragment contribution of donor parental
AAV serotype capsid sequences. One novel variant, a capsid
chimera between AAV2 and 3, demonstrated similar bind-
ing to the heparin sulfate surface receptor, but demonstrated
a useful technique for mapping capsid sequences required
for attachment or other functions that could alter tropism.41
Development of more chimeric capsid rAAVs resulted in
the ability to change receptor tropism and even virus traf-
ficking.42 Importantly, these works led to the generation of
chimeric capsid libraries that could be screened. This ‘‘di-
rected evolution’’ technique carried out by Wupin Li in the
lab allowed for generation of rAAV with increased tropism
for human airway epithelium eventually extended to in vivo
selection by post doc Steve Gray and long-time collaborator
Thomas McCown that resulted in new rAAV vectors that
cross the seizure-compromised blood–brain barrier.43,44
These studies led to the isolation of the first AAV capsid that
has a unique dominant tropism for ‘‘oligodendrocytes’’ and
strongly suggest that AAV capsids with selected tropism are
limited only by the selection procedure.
Lastly, an area that is not as explored includes cellular
trafficking of rAAV and its effect on tropism and trans-
duction success. Early studies examined the entry pathway,
finding rapid internalization by receptor-mediated endocy-
tosis from clathrin-coated pits and a rate-limiting step of
nuclear entry.45 Almost 10 years later, confocal microscopy
was used to track the subcellular fate of the virus and de-
termined that the microtubule network facilitated rAAV2
movement around the cell.46 It was also reported that a
population of rAAV2 enters the nucleus, while empty cap-
sids are excluded. The use of proteasome inhibitors and
siRNA against nucleolar protein B23 caused a synergistic
increase in transduction more than 50-fold. This work con-
firmed that rAAV enters the nucleus intact and that entry
can be enhanced through inhibition of multiple pathways.47
Additionally, mutation to basic amino acids of rAAV2
capsid VP1 protein resulted in reduced efficacy in trans-
formed cells, but indistinguishable infection to rAAV2 in
several nontransformed cell lines and tissue in vivo.48 The
outcome of these investigations yielded a new perspective
on entry pathways for ‘‘in vitro versus in vivo’’ settings.
Additional AAV trafficking studies determined that rAAV2
interacts with importin-b alone or in complex with other
karyopherins to facilitate nuclear entry,49 a critical step re-
quired for viral and vector infectivity.
Optimizing AAV Production
As study of AAV biology was continued during the 1990s,
production of high titers of purified rAAV for therapeutic
application required additional research. As mentioned above,
preliminary studies determined that second-strand synthesis
of the AAV ssDNA genome was the rate-limiting step for
efficient transduction by rAAVs.50 Unfortunately, it would be
5 years until the issue was fully addressed with the generation
of scAAV vectors in 2001 by Doug McCarty in the lab.37,38
Importantly though, the Ferrari article was the first to
demonstrate production of rAAV in a system free from in-
fectious Ad. Transfection with a helper plasmid lacking
required Ad replication sequences allowed for expression of
Ad genes needed for production of rAAV particles.50 Ad-
ditional progress toward a production protocol suited for
GMP was achieved when Xiao discovery that reduced AAV
Rep78/68 expression led to substantially higher yields of
rAAV.51 However, most significant for understanding vector
production was the advent of the pDD-2 plasmid.52 Focusing
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on the required components of virus replication, two trans-
acting Rep and Cap genes and cis-acting ITRs, a plasmid was
generated to contain a novel modified ITR of 165 bp con-
taining flanking D and D¢ sequences. The DD ITR is an
intermediate structure generated during viral DNA replication.
Having this substrate available for the Rep protein nicking
activity immediately following transfection facilitated their
resolution into linear replication substrates.52 This plasmid
intermediate provided direct evidence that resolution of the
ITR could be carried out in absence of Rep through a ‘‘Holi-
day’’ structure resulting in linear fragments with closed ‘‘no
end’’ substrates now suitable for replication. Further, Candace
Summerford discovered the first receptor used by AAV;
namely, that AAV2 host cell receptor was a membrane-asso-
ciated heparin sulfate proteoglycan. This was also demon-
strated to be useful for purification of rAAV particles.53,54
Work by Aravind Asokan, then a post doc, demonstrated
that an additional AAV2 receptor was utilized for produc-
tive infection; specifically integrin a5b155 adding to grow-
ing base knowledge of viral entry. Numerous labs have
added to our understanding of AAV receptors, providing a
rich resource of information currently being studied with
generation of ‘‘targeted vectors.’’ Production development
was being carried out in parallel and the first production
method completely free of Ad helper virus was demon-
strated.56 This method eliminated the need for develop-
ment of replication-competent Ad assays and provided a
more defined AAV reagent for clinical application.56 Ad-
ditionally, movement away from potentially toxic reagents
of CsCl for purification led to the ionic iodixanol gradients
followed by ion exchange chromatography developed by
colleagues in Florida.57 This method resulted in a 50% in-
crease in recovery from crude lysate and a vector that is
99% pure and is now being used for large-scale produc-
tion.57 With an optimized vector production method, viral
titers of 1012/liter were achieved, whereas previously res-
cued virus preparation provided titers of 107–8.51 Impo-
rtantly, vector production had reached yields where quantity
and purity were feasible for clinical application and various
protocols have now been published supporting these original
efforts.58 Production improvements continue with the recent
development of the UNC Pro10 suspension cell line by Josh
Grieger that is free of all animal and human products.
Translating Preclinical Research to Clinical Trials
Preclinical studies with AAV have led to many clinical
trials, reviewed in detail.59–63 The Samulski lab has been a
part of a handful of these trials, described below. However,
the significant contributions of others toward clinical ap-
plication of AAV must also be highlighted. On the basis of
the initial discovery of AAV2 and the amount of AAV2-
specific data, this was the first serotype to be used against
numerous diseases, including hemophilia B, cystic fibrosis,
Parkinson’s, Batten’s, Canavan’s, rheumatoid arthritis, Le-
ber’s congenital amaurosis, and age-related macular de-
generation. With the advent of generating ‘‘hybrid AAV’’
vectors, which utilized various AAV serotypes and viral
engineering techniques, AAV2 was joined in the clinic by
additional serotype vectors. First, to address issues with
tropism, serotypes with inherent tissue-specific tropism are
used. AAV1, first described by former student Weidong
Xiao, with its enhanced muscle tropism compared with AAV2,
is being explored for muscular gene delivery to treat a-1 an-
titrypsin deficiency, lipoprotein lipase deficiency, Pompe’s
disease, limb girdle muscular dystrophy, and cardiac failure.
AAV6 and 9 also demonstrate increased musculoskeletal tro-
pism as well as cardiac tropism. AAV5 and 9 may best fa-
cilitate gene transfer to the CNS. Further, AAV4 and 8 are
being explored for clinical use in the eye, with AAV8 being
utilized for successful factor IX phase I studies. Each serotype
with its unique biodistribution provides a potential method for
targeted delivery and enhanced efficacy in this first-generation
AAV approach and more natural serotypes were being isolated
and described by Guangping Gao in Jim Wilson’s group.
However, with the ability to clone and produce AAV2
came the ability to engineer the next generation of clinical-
grade rAAVs that were rationally designed to address issues
with clinical application such as toxicity, evasion of im-
mune response, de-targeting, and enhanced tissue tropism.
Shown by Zhong, Srivastava, and others, AAV capsid pro-
teins with tyrosine-to-phenylalanine substitutions have shown
enhanced transduction with reduced toxicity.64 The volume
of AAV structural data generated almost exclusively by
Mavis Agbandje-McKenna’s lab has set the backdrop to carry
out rational capsid mutagenesis. With exciting articles from
David Schaffer and Dirk Grimm in Mark Kay’s lab, as well
as others, the portfolio of AAV capsid options exploded.
Engineering of hybrid capsids also facilitates reduced tox-
icity and the ability to home tissue tropism. In general,
vectors that allow for enhanced gene delivery and expression
can be used in reduced concentrations. One such example en-
gineered in the Samulski lab resulted in AAV2.5, where the
muscle tropism determinants of AAV1 are combined with pa-
rental AAV2. This hybrid vector also allows for immune eva-
sion of neutralizing antibodies to AAV1 and 2.65 This led to the
first and only clinical trial using a chimeric AAV capsid for a
DMD phase I study. Currently, chimeric AAV capsids are lin-
ing up to enter clinical testing now that extensive preclinical
data have been generated. Additional hybrids have emerged: (1)
AAV6.2 that may prove beneficial for intravenous delivery,66
(2) AAV2i8 designed by Aravind Asokan in the lab that dem-
onstrates attenuate liver sequestration,67 and (3) AAVrh32.33
that induces an impaired T-cell response in the clinic.68,69
Beyond these initial hybrid vectors, chimeric capsid
proteins are a product of sequence or peptide libraries first
generated by Muller et al.70 Use of these libraries allows for
engineering and selection of rAAVs that are resistant to
neutralizing antibodies, have enhanced/targeted tissue tro-
pism, or can be used at reduced concentrations to produce
similar outcomes to parental vectors. Rational design also
led to scAAV. As mentioned previously, compared with
ssAAV, these vectors have the ability to produce more rapid
gene expression, but are limited to smaller genes or those
that have been optimized for the smaller vector genome size
of 2.5 kb. What these collaborative works mean for clinical
success is that we are now armed with limitless options to
discover and provide disease-specific rAAV.
Regarding the clinical trials involving the Samulski lab and
the UNC Gene Therapy Center, preclinical studies in rodent
and primate systems had demonstrated safety of AAV therapy
in the CNS, and the first clinical trial using rAAV2 (Fig. 1)71
for gene therapy in the human CNS was produced at UNC
vector core and conducted by Dr. Leone and colleagues.72
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Canavan’s disease, a rare leukodystrophy with no treat-
ment options, is caused by mutation to the aspartoacylase
(ASPA) gene and prevents normal myelination as a result of
increased levels of N-acetylaspartate (NAA). The trial enlisted
pediatric patients naı̈ve to previous nonviral gene transfer
and administered AAV2-ASPA via neurosurgical adminis-
tration. Neutralizing antibodies were not found in 7/10 patients
and in all patients minimal signs of inflammation or immune
stimulation were noted. Long-term monitoring of patients
was conducted to determine efficacy.73 Significantly, no ad-
verse effects from vector administration were observed.
Moreover, in patients treated with rAAV2-ASPA, there were
decreased levels of NAA and slowed progression of brain
atrophy, improved seizure frequency, and stabilized clinical
status.73 This clinical study benefited from the concomitant
development of vector design and production, both of which
initiated a hand-in-hand approach that would be adopted for
future clinical efforts. More importantly, from these early
clinical studies, it has now been determined that targeting
gene transfer to oligos is the ideal target, and phase II studies
utilizing novel oligo tropic AAV capsid for targeted delivery
are being contemplated and should demonstrate signifi-
cant improvement based on preclinical data. A single theme
emerging is that identifying the correct AAV capsid for a
genetic disorder (e.g., muscle versus liver tropic) will provide
the best opportunity to obtain meaningful clinical results.
Focusing next on hemophilia, in a preclinical canine model
carried out by Paul Monahan in the lab, i.m. delivery of
rAAV encoding hFIX under control of a CMV promoter was
well tolerated and resulted in transient reduction in whole
blood clotting time.74 Antibodies were generated against the
hFIX, and expression continued at least 10 weeks after vector
administration. This first large animal study suggested safety
following i.m. delivery and encouraged development of gene
therapy for human diseases. Additional large animal research
with rAAV and nonhuman primates demonstrated successful
transduction without toxicity.75
Follow-up work to the canine hFIX study began exam-
ining the effect that viral capsid modification could have on
murine muscle cell transduction and human or canine FIX
secretion.76 This work highlighted the use of alternative
serotypes for tissue-specific treatments, demonstrating that
rAAV2, while best for in vitro transduction, was not optimal
in vivo compared with rAAVs 1, 3, or 5.76 In fact, this led to
work where rAAV1 encoding FIX treatment of hemophilia
B mice causes a sustained and complete phenotype correc-
tion.77 Work by other labs in a phase I/II dose escalation
clinical trial from 2001 to 2004 determined that the therapy
was safe, but that transient FIX expression caused by immune
clearance of transduced cells prevented a permanent solu-
tion.78 Follow-up work examined the prevalence of NAbs
in 62 children with hemophilia A. This study demonstrated
that prior exposure to rAAV2 produced NAbs with partial
cross reactivity for rAAV5 and 8 and may guide rational
design of future trials.79 The information gathered from the
previous trial and patient samples, coupled with the advent
of scAAV, led to an ongoing phase I/II clinical using
scAAV8FIX led by Amit Nathwani and scAAV8.FIXR338L
trial lead by Paul Monahan.80 The R338L variant of FIX
allows for increased specific activity and can achieve ther-
apeutic success at lower concentrations than wt FIX. The
study by Nathwani supports long-term correction (now more
than 3 years). This novel UNC vector is in phase 1 studies
and preliminary results are supportive of the mouse studies.
The UNC FIX experience strongly supports the value of the
‘‘bench to bedside, back to bench, etc.’’ approach, and the
hope is that this novel vector should yield a commercial
product within the next 5–7 years.
As briefly described above, building on the work of the
capsid modification for enhanced efficacy, the first clinical trial
using a chimeric rAAV2.5 (a chimera of AAV2 with five
mutations from AAV1) that combines improved muscle
transduction with reduced antigenic cross reactivity against
both serotypes was carried out.65 DMD is caused by a mutation
to the dystrophin gene and was predicted to be correctable with
gene therapy. rAAV2.5-mediated delivery of a novel mini-
dystrophin gene developed by Xiao was shown to improve the
lifespan of dystrophin-deficient mice without significant tox-
icity.81,82 In the trial, vector injection was done via the bicep
muscle in one arm and a saline control or empty vector in the
contralateral arm. Injection of empty vector to patients was
meant to allow for distinguished immune response between the
rAAV or the minidystrophin transgene. Significantly, no im-
mune response to the rAAV2.5 capsid was detected and the
safety of the vector was established.65,83 Long-term monitor-
ing is ongoing with new phase II studies looking at limb in-
fusion with long-term objective of rescuing upper limb
mobility followed by systemic whole-body gene transfer in
DMD patients. Additional chimeric capsids are being devel-
oped to assist these clinical efforts and optimization is high.
More recently, work with giant axonal neuropathy (GAN)
is moving forward toward early clinical testing. Caused by
loss of function of the gigaxonin protein, GAN is charac-
terized by aggregation of intermediate filaments (IF) that
results in fatal neuropathy. This was the first study to dem-
onstrate that re-introduction of the GAN gene to deficient
cells would restore cytoskeleton IF homeostasis. Pre-
liminary testing was conducted on GAN patient primary
skin fibroblast cultures. Treatment with rAAV2 encoding
the human GAN transgene caused significant reduction in the
number of cells displaying IF aggregation.84 Moving in vivo,
GAN mice that received intracisternal injection of rAAV9
encoding a CMV promoter and the GAN gene resulted in
global deliver to the CNS. By 3 weeks postinjection, treated
animals showed a nearly complete clearance of IF accumu-
lation.84 To address concerns of GAN overexpression-related
toxicity, a weak synthetic JeT promoter will be tested against
CMV and to increase transduction efficiency an scAAV has
been generated. This phase 1 study was recently approved
and is recruiting patients for initiation of clinical studies
February this year. While numerous AAV capsids and clin-
ical indications are marching into the clinic, the UNC vector
core generated GMP vector for the first-ever gene transfer
study in Australia for wet age-related macular degeneration.
This clinical focus was related to ocular gene transfer for
macular degeneration using the original AAV2 vector gen-
erated in 1982 in the lab of Nick Muzyczka at University of
Florida and still appears to be a suitable workhorse for some
clinical indications.
Ongoing Challenges and Future Application
With the many successes of AAV gene therapy in the last
50 years, key discoveries about virus biology, improved
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methods of vector production, and positive effects seen in
long-term clinical trials, it remains clear that there is always
room for improvement. Ongoing challenges to evade neu-
tralizing antibody responses to treatment are still being met
with novel capsid generation as well as improved vector
delivery. A lot of continued work is examining the immune
clearance of transduced cells and has noted that rAAV capsid
antigen presentation is dependent on endosomal escape.85
Further, single amino acid changes in the capsid proteins
result in vectors with less immunogenicity and improved
transduction.86 Limitations to vector packaging size also
continue to be explored and may soon result in generation of
vectors with room for larger transgene inserts.87 Finally, in
preclinical exploration and clinical testing, rAAV-mediated
therapies have only been applied to the tip of the iceberg
regarding the more than 7,000 rare diseases that remain a
scourge. Significant advances have been made in retinal
diseases and approximately 40% of ongoing clinical trials are
focused on ocular-related disease. One certainty with all of
this ongoing research is that the future of AAV, on the cusp
of clinical approval in the United States, is bright and will
have a lasting impact on the many individuals amendable to
AAV-mediated gene therapy.
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